Unichem Laboratories Limited · NSE:UNICHEMLAB
Unichem Laboratories — Q2 FY2009-10 Earnings Presentation
6 slides from Unichem Laboratories's earnings presentation, Oct 22, 2009
Slide 1: Investor Update: Q2 FY 09-10 Financial Performance
INVESTOR UPDATE BSE: 506690 NSE: UNICHEMLAB Reuters: UNLB.BO Bloomberg: UN@IN Mumbai, October 22, 2009 UNICHEM LABORATORIES LIMITED Q2 FY 09-10: Financial Performance Table of Contents Financial Highlights ORG / IMS Ranking Page 1 of 6
Slide 2: Financial Highlights: Q2 FY 2009-10
INVESTOR UPDATE Financial Highlights: Q2 – FY 2009-10 • The company’s revenue from operations stood at Rs. 174.65 crs during the quarter under review against Rs. 176.71 crs recorded during the comparable period o The revenue fall is essentially due to lower exports and rationalization of product sch
Slide 3: Analysis of Quarterly & Half Yearly Financial Results
INVESTOR UPDATE Analysis of Quarterly & Half Yearly Financial results for the year ended 30th Sept, 2009. Rs. In Lacs STAND ALONE FINANCIALS For three For three For six For six months months months months % % Particulars ended ended ended ended Growth Growth Sep 30, Sep 30, Sep 30, Sep 30, 2009 2008
Slide 4: Niche Generics Sales and Financial Ratios
INVESTOR UPDATE Niche Generics Limited, our United Kingdom subsidiary recorded sales of GBP 2.66 millions for the quarter ended Sept 30, 2009 as compared to GBP 2.85 millions for the quarter ended Sept 30, 2008 . Ratios Quarter ended Quarter Previous year Previous year Sept 30, ended Sept ended Marc
Slide 5: India Formulation Business Key Highlights: ORG-IMS
INVESTOR UPDATE India Formulation Business Key Highlights ORG-IMS Domestic formulations market during MAT August’09 is estimated by ORG-IMS to be Rs.37384crores with a growth of 12.4% over MAT August’08. Unichem Laboratories worth Rs.543crs with a share of 1.45% ranks 26th and has grown at 4.4%. The
Slide 6: Brand Position and About Unichem Laboratories
INVESTOR UPDATE Brand Position Three Unichem brands feature among the top 100 Indian pharmaceutical brands during MAT August.’09. 1. Ampoxin – Rs.76crs. (Rank 31st) 2. Losar-H – Rs.53crs. (Rank 65th) 3. Losar – Rs.49crs. (Rank 71st) Prescription audit - CMARC As per the latest CMARC 4-monthly March-
Unichem Laboratories — Q2 FY2009-10 Earnings Presentation on 6ix